

Antimicrobial Susceptibility, Acid-Fast Bacilli, Slowly Growing, Varies

Patient ID SA00141164	Patient Name SAMPLEREPORT, MMLSG	Birth Date 1949-11-27	Gender F	Age 71
Order Number SA00141164	Client Order Number SA00141164	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 29 Dec 2020 05:43		

Susc, AFB, Slowly Growing

MCR



Abn

SOURCE: SPUTUM
SUSC, AFB, SLOWLY GROWING
FINAL
MYCOBACTERIUM AVIUM COMPLEX

Organism identified by client.

There are no established interpretive guidelines for agents reported without interpretations.

Organism: MYCOBACTERIUM AVIUM COMPLEX		
Antibiotic	MIC (mcg/mL)	Interpretation
Clofazimine	0.25	
Moxifloxacin	0.12	S
Clarithromycin	0.5	S
Amikacin (IV)	4	S
Amikacin (liposomal, inhaled)	4	S
Linezolid	4	S

Moxifloxacin: The in vivo effectiveness of this agent for MAC disease is unproven.

Clarithromycin: Clarithromycin is the class drug for macrolides and the only macrolide that needs to be tested.

Linezolid: The in vivo effectiveness of this agent for MAC disease is unproven.

S=SUSCEPTIBLE I=INTERMEDIATE R=RESISTANT
NS=NONSUSCEPTIBLE SDD=SUSCEPTIBLE DOSE
DEPENDENT

Received: 29 Dec 2020 13:40

Reported: 29 Dec 2020 13:42

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Report Status: Final